Here is how Ginkgo Bioworks Holdings Inc (DNA) stock might take investors finances to the next level

Ginkgo Bioworks Holdings Inc [DNA] stock is trading at $1.53, up 9.29%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The DNA shares have gain 11.68% over the last week, with a monthly amount glided 18.60%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

On 27, February 2024, Ginkgo Biosecurity Launches Doha-Based Pathogen Monitoring Center, CUBE-D, Establishing Middle East Hub for Global Bioradar, at Qatar Free Zones. In a post published today on Yahoo Finance, The center will be a first of its-kind collection and analysis center for data gathered through Ginkgo’s pathogen monitoring network.

From an analyst’s perspective:

Ginkgo Bioworks Holdings Inc [NYSE: DNA] stock has seen the most recent analyst activity on November 14, 2023, when Raymond James downgraded its rating to a Mkt Perform and also revised its price target to $2.50 from $3.50. Previously, BTIG Research downgraded its rating to Neutral on November 09, 2023. On June 02, 2023, downgrade downgraded it’s rating to Sell and revised its price target to $1.25 on the stock. William Blair downgraded its rating to a Mkt Perform. Berenberg initiated its recommendation with a Buy and recommended $6 as its price target on November 29, 2022. Morgan Stanley started tracking with a Equal-Weight rating for this stock on October 04, 2022, and assigned it a price target of $5. In a note dated May 18, 2022, BofA Securities downgraded an Underperform rating on this stock but restated the target price of $3.

Ginkgo Bioworks Holdings Inc [DNA] stock has fluctuated between $1.12 and $2.55 over the past year. Currently, Wall Street analysts expect the stock to reach $7.09 within the next 12 months. Ginkgo Bioworks Holdings Inc [NYSE: DNA] shares were valued at $1.53 at the most recent close of the market. An investor can expect a potential return of 363.4% based on the average DNA price forecast.

Analyzing the DNA fundamentals

Ginkgo Bioworks Holdings Inc [NYSE:DNA] reported sales of 314.99M for the trailing twelve months, which represents a drop of -16.52%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4367 points at the first support level, and at 1.3433 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5867, and for the 2nd resistance point, it is at 1.6433.

Ginkgo Bioworks Holdings Inc [DNA] reported earnings per share of -$0.16 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.09/share, meaning a difference of -$0.07 and a surprise factor of -77.80%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.09 per share as compared to estimates of -$0.08 per share, a difference of -$0.01 representing a surprise of -12.50%.

Ratios To Look Out For

For context, Ginkgo Bioworks Holdings Inc’s Current Ratio is 6.78. In addition, the Quick Ratio stands at 6.78 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 9.71, the price to book ratio is 2.26.

Transactions by insiders

Recent insider trading involved Dmytruk Mark E.,, that happened on Feb 02 when 39569.0 shares were sold., Kelly Jason R completed a deal on Jan 04 to sell 100000.0 shares. Meanwhile, Kelly Jason R sold 100000.0 shares on Jan 03.

Related Posts